FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average I	burden						
hours per response	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	e Responses)																	
1. Name and Address of Reporting Person *- Gold Mark Stephen				2. Issuer Name and Ticker or Trading Symbol Axogen, Inc. [AXGN]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_ Director 10% Owner					
13631 PROGRESS BOULEVARD, SUITE 400				3. Date of Earliest Transaction (Month/Day/Year) 06/01/2022								_	Officer (give tit	le below)	Other	specify below)	
(Street) ALACHUA, FL 32615				4. If Amendment, Date Original Filed(Month/Day/Year)								_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City))	(State)	(Zip)				Table	I - Nor	n-Deri	ivative Se	curitie	es Acquired	ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Yea	Exec ar) any			(Instr. 8)		(<i>A</i>	1. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		f (D) Own Trai	5. Amount of Securi Owned Following R Transaction(s) (Instr. 3 and 4)) H	Ownership Form:	7. Nature of Indirect Beneficial Ownership		
				(WIOI	iiii/L	Jay/Tear)	Code	e ,	V A	amount	(A) or (D)		o		or Indirect (Instr. 4)			
Common S	Stock		06/01/2022				M		3. (1	,036	A	\$ 0 305	5,475 (2)		I)		
1. Title of Derivative Security (Instr. 3)	Table II - Derivative Securities Acquired, Disposed of, or I (e.g., puts, calls, warrants, options, convertible so of Conversion Date Conversion Of Execution Date, if Of Execution Date, if Of Code Securities Code Code Currently valid Ol Currently valid Valid V				MB c Benef	ontrol nunicially Ownies) 7. Title and	Owned e and Amount of lying Securities 8. Price of Derivative		9. Number of Derivative Securities Beneficially Owned Following		ve Ownershi : (Instr. 4)							
				Code	V	(A)	(D)	Date Exerc	eisable	Expiration Date	on	Title	Amount or Number of Shares		Reported Transaction(s (Instr. 4)	or Indirec		
Restricted Stock Units	(3)	06/01/2022		M			3,036	Ú	<u>(4)</u>	<u>(4</u>	Ð	Common Stock	3,036.00	\$ 0	0	D		
Restricted Stock Units	(3)	06/01/2022		A		6,459		1	(5)	<u>(5</u>	<u>n</u>	Common Stock	6,459.00	\$ 0	6,459	D		
Stock Option (right to purchase)	\$ 9.29	06/01/2022		A		11,811		1	<u>(5)</u>	06/01/2	2032	Common Stock	11,811.00	\$ 0	11,811	D		

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Gold Mark Stephen 13631 PROGRESS BOULEVARD SUITE 400 ALACHUA, FL 32615	X					

Signatures

/s/Dr. Mark Gold	06/03/2022
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This reflects the number of restricted stock units that vested on June 1, 2022.
- (2) The shares of common stock for Dr. Gold include 31,900 shares held directly, 159,575 shares held jointly by Dr. Gold and his wife, indirect ownership of 22,000 shares held by Dr. Gold's spouse in revocable trusts, and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust.
- (3) Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
- (4) Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a \$120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.
- Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a \$120,000 valuation as of the grant date and (5) vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.